Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 31, 2002

View Archived Issues

5G1.1 enters phase IIb trial in rheumatoid arthritis

Results from new collaboration between Alfacell and University of Frankfurt

In vivo Abeta amyloidogenic process inhibited by NC-531, a new GAG mimetic

Significant and sustained improvement seen on Exelon in subcortical vascular dementia

Effect of RPR-115135 on cytotoxicity of 5-FU in human tumor cells with different p53 status

Antiinflammatory effects demonstrated for adenosine uptake inhibitor in LPS-treated mice

Zelmac approved in Australia for symptomatic relief of IBS in women

Zoladex LA receives approval in Japan for prostate cancer

Italian researchers identify promising lead in search for third-generation NNRTIs

Enrollment completed in phase II at-home study of Femprox

Avanir outlicenses docosanol to Biopharm for Middle East and Gulf territories

Immune Network and Imaging Research Solutions to study dapsone in AD

Board recommends continuation of Biomira's phase IIb trial of BLP25 in NSCLC

Efficacy of levodopa in PD confirmed at international meeting

Phospholipid useful as antiinfluenza virus agent

Prostaglandin analogues claimed for use in congestive heart failure

Development of selective human PPARalpha activator reported by Kyorin

Sanofi-Synthelabo identifies new series of beta3-adrenoceptor agonists

AstraZeneca describes use of 4-aminoquinazoline derivatives in the treatment of solid tumors

New NOS inhibitors synthesized at Aventis

Toyama discloses novel benzophenone derivatives for use in arthritis in recent patent

Increased striatal dopaminergic function in schizophrenia linked to prefrontal cortical dysfunction

Two series of HMG-CoA reductase inhibitors with utility in lipid metabolism disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...